News
SVA
6.47
0.00%
0.00
Weekly Report: what happened at SVA last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at SVA last week (0408-0412)?
Weekly Report · 04/15 09:09
Weekly Report: what happened at SVA last week (0401-0405)?
Weekly Report · 04/08 09:10
Weekly Report: what happened at SVA last week (0325-0329)?
Weekly Report · 04/01 09:10
Weekly Report: what happened at SVA last week (0318-0322)?
Weekly Report · 03/25 09:10
Weekly Report: what happened at SVA last week (0311-0315)?
Weekly Report · 03/18 09:10
Weekly Report: what happened at SVA last week (0304-0308)?
Weekly Report · 03/11 09:09
Weekly Report: what happened at SVA last week (0226-0301)?
Weekly Report · 03/04 09:10
Weekly Report: what happened at SVA last week (0219-0223)?
Weekly Report · 02/26 09:11
Weekly Report: what happened at SVA last week (0212-0216)?
Weekly Report · 02/19 09:11
Weekly Report: what happened at SVA last week (0205-0209)?
Weekly Report · 02/12 09:10
Weekly Report: what happened at SVA last week (0129-0202)?
Weekly Report · 02/05 09:11
Weekly Report: what happened at SVA last week (0122-0126)?
Weekly Report · 01/29 09:10
Weekly Report: what happened at SVA last week (0115-0119)?
Weekly Report · 01/22 09:11
Sinovac Board Rejects Partial Tender Offer By Alternative Liquidity Index - Quick Facts
NASDAQ · 01/18 12:09
Weekly Report: what happened at SVA last week (0108-0112)?
Weekly Report · 01/15 09:10
Weekly Report: what happened at SVA last week (0101-0105)?
Weekly Report · 01/08 09:11
Weekly Report: what happened at SVA last week (1225-1229)?
Weekly Report · 01/01 09:10
Weekly Report: what happened at SVA last week (1218-1222)?
Weekly Report · 12/25/2023 09:11
Weekly Report: what happened at SVA last week (1211-1215)?
Weekly Report · 12/18/2023 09:11
More
Webull provides a variety of real-time SVA stock news. You can receive the latest news about Sinovac Biotech Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SVA
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.